(J Am Heart Assoc. 2020;9:e016110 DOI: 10.1161/JAHA.120.016110.)32223392

The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

At present, implantable left ventricular assist devices (LVADs) represent the only available and effective alternative to heart transplantation for end‐stage heart failure, and may be utilized within a broad spectrum of indications, including bridge to heart transplantation or recovery, or destination therapy. Right ventricular (RV) function is an independent prognostic factor in patients with chronic heart failure.[1](#jah34986-bib-0001){ref-type="ref"} RV failure after LVAD implantation for chronic heart failure treatment portends a particularly poor prognosis. However, many aspects of RV failure following LVAD implantation are still uncertain. What has been observed is that immediately after device implantation, the left ventricle is decompressed, causing a leftward shift of the interventricular septum, which reduces its mechanical contractile properties. In addition, RV output must match the flow generated by the device. In this setting, the RV is sensitive to its afterload, which is driven by elevated left atrial pressure and is further increased by elevated small vessel resistance in the setting of preexisting heart failure, operative stress, inflammation, and shear stress. Several hemodynamic parameters have been examined to reflect RV afterload in pulmonary hypertension caused by left heart disease, including the diastolic pulmonary artery to pulmonary capillary wedge pressure difference or gradient (DPG).[2](#jah34986-bib-0002){ref-type="ref"}

In this issue of the *Journal of the American Heart Association* (*JAHA*), Imamura and colleagues[3](#jah34986-bib-0003){ref-type="ref"} investigated the impact of a DPG \>5 mm Hg on outcomes of LVAD assessed by right heart function measurements with echocardiography and hemocompatibility‐related adverse events. While this is a small study (92 patients, with few data on the pre‐LVAD hemodynamics), and even fewer data (≈69 patients undergoing complete RV functional measurements), it presents novel, clinically meaningful data.

Research in the area of precapillary pulmonary hypertension has seen major advances over the past years in terms of genetics, vascular biology, and treatments, but PH‐LHD has generally remained poorly understood. In the current work, Imamura and colleagues[3](#jah34986-bib-0003){ref-type="ref"} have utilized a DPG of \>5 mm Hg in a prospective study setting to predict outcomes after LVAD implantation. A threshold of 5 has been described in early work[4](#jah34986-bib-0004){ref-type="ref"} to discriminate cardiac from pulmonary causes of increased vascular resistance. Imamura and colleagues[3](#jah34986-bib-0003){ref-type="ref"} found that almost half of the patients (48%) had a DPG \>5 mm Hg, suggesting a pulmonary vascular disturbance. Of 71 patients who had pre‐LVAD hemodynamic data, 33 had post‐LVAD DPG \>5 mm Hg, with 13 of 33 who had persistent DPG \>5 mm Hg before and after LVAD implantation, and 20 of 33 who experienced a de novo elevation of DPG \>5 mm Hg. The authors' main finding was a DPG \>5 mm Hg irrespective of pulmonary artery wedge pressure in almost 50% of clinically stable LVAD patients. A DPG \>5 mm Hg was associated with worsening RV function and a higher incidence of RV failure within 10 months after LVAD implantation, and significantly higher rates of hemocompatibility‐related adverse events, which defines any nonsurgical bleeding, thromboembolic event, pump thrombosis, or neurological events.

While, for example, the elevation in the right atrial to pulmonary artery wedge pressure (RA/pulmonary artery wedge pressure) ratio may be a hemodynamic marker for poor postoperative outcomes including length of stay and RV function in patients undergoing LVAD implantation,[5](#jah34986-bib-0005){ref-type="ref"} DPG is a novel hemodynamic biomarker for LVAD outcomes. In the past, DPG has mainly been used to diagnose pulmonary causes of heart failure,[4](#jah34986-bib-0004){ref-type="ref"} or to prognosticate pulmonary hypertension caused by left heart disease. RV afterload is driven by elevated left atrial pressure in isolated postcapillary PH. When mean pulmonary artery pressure is disproportional to left atrial pressure because of a contribution of arterial and venous pulmonary vascular disease,[6](#jah34986-bib-0006){ref-type="ref"} combined post‐ and precapillary PH is present.[7](#jah34986-bib-0007){ref-type="ref"} According to a large hemodynamic database,[7](#jah34986-bib-0007){ref-type="ref"} combined post‐ and precapillary PH is predicted by a DPG ≥7 mm Hg, and associated with decreased right ventricular‐pulmonary vascular coupling and increased mortality.[8](#jah34986-bib-0008){ref-type="ref"} The prognostic relevance of DPG has been confirmed in some reports,[2](#jah34986-bib-0002){ref-type="ref"}, [8](#jah34986-bib-0008){ref-type="ref"}, [9](#jah34986-bib-0009){ref-type="ref"}, [10](#jah34986-bib-0010){ref-type="ref"}, [11](#jah34986-bib-0011){ref-type="ref"}, [12](#jah34986-bib-0012){ref-type="ref"}, [13](#jah34986-bib-0013){ref-type="ref"}, [14](#jah34986-bib-0014){ref-type="ref"}, [15](#jah34986-bib-0015){ref-type="ref"}, [16](#jah34986-bib-0016){ref-type="ref"}, [17](#jah34986-bib-0017){ref-type="ref"}, [18](#jah34986-bib-0018){ref-type="ref"} but has also been refuted by others[19](#jah34986-bib-0019){ref-type="ref"}, [20](#jah34986-bib-0020){ref-type="ref"}, [21](#jah34986-bib-0021){ref-type="ref"}, [22](#jah34986-bib-0022){ref-type="ref"}, [23](#jah34986-bib-0023){ref-type="ref"} ([Table](#jah34986-tbl-0001){ref-type="table"}). Because of discordant data sets that are mainly based on discordant populations of patients, the 2018 World Meeting on Pulmonary hypertension groups have redefined postcapillary PH as mean pulmonary artery pressure \>20 mm Hg and PAWP \>15 mm Hg; and if these criteria apply, then isolated postcapillary‐PH is defined by a PVR ≤3 (Wood Units); and combined post‐ and precapillary PH is defined when PVR \>3 WU, thus eliminating DPG from the definition.[24](#jah34986-bib-0024){ref-type="ref"}

###### 

DPG as Predictor of Survival in PH‐LHD

  Study                                                                                            N        Model           Predictive Role of DPG
  ------------------------------------------------------------------------------------------------ -------- --------------- ------------------------
  Gerges C et al *Chest* 2013[2](#jah34986-bib-0002){ref-type="ref"}                               1094     Multivariable   \+
  Tedford RJ et al *J Heart Lung Transplant* 2014[19](#jah34986-bib-0019){ref-type="ref"}          16 811   Univariable     −
  Tampakakis et al *JACC Heart Fail* 2015[20](#jah34986-bib-0020){ref-type="ref"}                  469      Multivariable   −
  Dragu R et al *Eur J Heart Fail* 2015[9](#jah34986-bib-0009){ref-type="ref"}                     164      Univariable     \+
  Zotter‐Tufaro C et al *JACC Heart Fail* 2015[10](#jah34986-bib-0010){ref-type="ref"}             148      Multivariable   \+
  Al‐Naamani N et al *JACC Heart Fail* 2015[21](#jah34986-bib-0021){ref-type="ref"}                73       Univariable     −
  Gerges M et al *AJRCCM* 2015[8](#jah34986-bib-0008){ref-type="ref"}                              1454     Multivariable   \+
  O\'Sullivan CJ, et al *Circ Cardiovasc Intervent* 2015[11](#jah34986-bib-0011){ref-type="ref"}   325      Multivariable   \+
  Mazimba S et al *Respir Med* 2016[12](#jah34986-bib-0012){ref-type="ref"}                        225      Multivariable   \+
  Rezaee ME et al *Clin Cardiol* 2016[13](#jah34986-bib-0013){ref-type="ref"}                      510      Univariable     \+
  Yamabe S et al *Circ J* 2016[14](#jah34986-bib-0014){ref-type="ref"}                             243      Univariable     \+
  Ibe T et al *J Cardiol* 2016[15](#jah34986-bib-0015){ref-type="ref"}                             164      Univariable     \+
  Naeije R et al *Circ Heart Fail* 2017[16](#jah34986-bib-0016){ref-type="ref"}                    636      Multivariable   \+
  Brunner NW et al *Catheter Cardiovasc Interv* 2017[22](#jah34986-bib-0022){ref-type="ref"}       133      Multivariable   −
  Palazzini M et al *Eur J Heart Fail* 2018[23](#jah34986-bib-0023){ref-type="ref"}                276      Univariable     −
  Vanderpool R et al *JAMA Cardiol* 2018[17](#jah34986-bib-0017){ref-type="ref"}                   10 023   Multivariable   \+
  Albers EL et al *Pediatr Transplan*t 2018[18](#jah34986-bib-0018){ref-type="ref"}                1468     Multivariable   \+
  Alnsasra A et al *JAHA* 2019[25](#jah34986-bib-0025){ref-type="ref"}                             268      Multivariable   \+

DPG indicates diastolic pulmonary artery to pulmonary capillary wedge pressure difference or gradient; and PH‐LHD, pulmonary hypertension caused by left heart disease.

While the data of Imamura and colleagues[3](#jah34986-bib-0003){ref-type="ref"} lend further support to the meaningfulness of DPG, their study is limited by a lack of follow‐up data and information on medical therapy changes. A further limitation is the authors' use of the term diastolic pulmonary artery pressure to pulmonary artery wedge pressure (*PADP‐PCWP*) *decoupling* for the description of a DPG of \>5 mm Hg. In pulmonary hypertension, the RV adapts to the increasing vascular load by enhancing contractility to maintain flow, which is termed "coupling." "Coupling" is a measure of energy transfer from the RV to the pulmonary circulation and can be assessed from the ratio between end‐systolic elastance and arterial elastance. While DPG may serve as a surrogate for pulmonary small vessel resistance that is a strong determinant of ventriculoarterial coupling, the authors' use of the term *decoupling* must be carefully separated from the term *uncoupling*, which describes RV failure from a conductance catheterization standpoint.

Taken together, Imamura and colleagues[3](#jah34986-bib-0003){ref-type="ref"} provide new support for the role of pulmonary resistance vessels determining RV afterload and outcomes after LVAD implantation, and for the concept that DPG may serve as a "hemodynamic lung biopsy."
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